Related Experiment Video
Updated: Jul 22, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Adherence, per-protocol effects, and the estimands framework.
1KeeneONStatistics, Berkshire, UK.
The traditional dichotomy of treatment effects in clinical trials, ITT or per-protocol, is insufficient. The ICH E9 (R1) estimands framework offers a better approach for defining treatment effects, considering intercurrent events.
Area of Science:
- Clinical Trials Methodology
- Statistical Analysis in Medicine
- Pharmaceutical Research
Background:
- Traditional statistical literature often simplifies treatment effects in clinical trials to either intention-to-treat (ITT) or per-protocol (PP) effects.
- The concept of 'per-protocol' effect and 'adherence' is frequently confusing, especially for non-statisticians, leading to misinterpretations of trial outcomes.
- Existing definitions of adherence and per-protocol effects do not adequately address the complexities of real-world clinical trial conduct, such as treatment discontinuation or the use of rescue medication.
Purpose of the Study:
- To highlight the limitations of the traditional ITT versus per-protocol dichotomy for describing treatment effects in clinical trials.
- To advocate for the adoption of the ICH E9 (R1) estimands framework for a more precise and clinically relevant definition of treatment effects.
- To emphasize the importance of clearly defining estimands and handling intercurrent events in clinical trial design and analysis.
Main Methods:
- Critically review the statistical literature's definitions and applications of intention-to-treat (ITT) and per-protocol (PP) effects.
- Analyze the ambiguities and clinical irrelevance arising from the simplistic ITT/PP dichotomy.
- Introduce and explain the principles of the ICH E9 (R1) estimands framework for defining treatment effects.
Main Results:
- The traditional ITT and per-protocol effect dichotomy is inadequate for capturing the range of clinically relevant treatment effects.
- The terms 'per-protocol' and 'adherence' are often poorly defined and lead to confusion among researchers and clinicians.
- The ICH E9 (R1) estimands framework provides a structured and comprehensive approach to defining treatment effects by explicitly considering intercurrent events.
Conclusions:
- The statistical literature should move beyond the simplistic ITT versus per-protocol framework for describing treatment effects.
- Implementing the ICH E9 (R1) estimands framework is crucial for improving the clarity and clinical relevance of treatment effect definitions in clinical trials.
- Proper definition and handling of intercurrent events within the estimands framework are essential for robust clinical trial interpretation.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Regression Toward the Mean
Confounding in Epidemiological Studies
What are Estimates?
The estimate for the mean of a sample is denoted by ͞x, whereas the mean of the population is designated as μ. Further, parameters such...
Blind Procedures
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...

